Skip to main content
News
Events
Contact us
Close Search
search
Menu
About us
About us
Team
Work with us
Our offering
Our offering
FAQs
Portfolio
Success stories
Partners
Apply
Apply
FAQs
search
Success stories
Many of our
portfolio companies
have had great successes. From raising money (collectively over $800M so far) to closing partnerships to being acquired. On some of them, you can read more below.
Success story Engimmune
Success story Cimeio
Success story Synendos
Success story Anaveon
Success story Alentis
Latest news
Filter
All
All
Company interviews
Featured
Features
Interviews
Portfolio news
Team interviews
Uncategorized
All
Gibela Therapeutics joins BaseLaunch portfolio
All
What’s the ideal deal structure to secure funding for biotech startups?
All
Alentis announces positive topline results from two studies of Lixudebart
All
Anaveon appoints Dr. Richard Sachse as Chief Medical Officer
All
Stromal publishes groundbreaking research in Cell
All
Looking for an experienced biopharma professional for CEO role
All
Cimeio Therapeutics announces partnership with Kyowa Kirin to develop Novel Cell Therapies
All
metaLead joins BaseLaunch portfolio
All
Alentis Therapeutics raises $181.4 million in an oversubscribed series D financing
All
Synendos secures Innosuisse funding to advance clinical development of SYT-510
All
Key strategies for biotech companies transitioning from early- to late-stage
All
Alentis Therapeutics receives FDA IND clearance for ALE.P02, a novel CLDN1-ADC for the treatment of squamous cancers
All
MT-act joins BaseLaunch portfolio
All
We welcome Hoffmann & Partner as our new domain partner
All
BaseLaunch summer get-together 2024
All
NXI Therapeutics extends pre-seed funding to CHF 3.5 million ahead of major seed round
All
9 tips for scientists who want to become entrepreneurs
All
Nature publication demonstrating Cimeio`s transformative approach towards blood cancers
All
AbbVie becomes a BaseLaunch partner
All
Alentis appoints Alberto Toso Chief Scientific Officer
All
Our partnership with CSL
All
We welcome VISCHER as our new domain partner
Uncategorized
Podcast: How to build a compelling pitch deck for early stage ventures
All
KPMG renews partnership with BaseLaunch
All
Features
FimmCyte obtains CHF 1 million from the UZH Life Sciences Fund
All
Features
Synendos Therapeutics granted EMA clinical trial authorisation
All
Features
William Pao joins Alentis Therapeutics as independent board member
All
Features
Novo Nordisk becomes a BaseLaunch partner
All
Features
Engimmune Therapeutics strikes ‘fast-forward’ micro-fluidics collaboration with Swiss innovator CSEM
All
Features
Ferring and PharmaBiome enter a collaboration and exclusive licensing agreement
All
Features
TOLREMO treats first patient in phase I trial with TT125-802, a novel therapeutic agent to overcome transcriptional cancer drug resistance
All
Features
T3 Pharma acquired by Boehringer Ingelheim for up to 450M Swiss francs
All
Features
FDA clears Versameb’s VMB-100 for stress urinary incontinence treatment
All
Features
Alentis Therapeutics doses first patient in phase 1/2 clinical trial of ALE.C04
All
Features
FimmCyte announces the appointment of Dr. Markus Kalousek as chairperson
All
Features
Onena Medicines secures 3.7 M Swiss francs investment
All
Features
Johnson & Johnson Innovation renews its commitment
All
Featured
Portfolio news
Cimeio collaborating with the University of Pennsylvania
All
Features
Insights into Roche’s partnering and venture fund strategies
All
Salvina Therapeutics joins BaseLaunch portfolio
All
Featured
Portfolio news
TOLREMO therapeutics secures USD 39 million
All
Featured
Portfolio news
Alentis Therapeutics receives FDA Fast Track Designation for ALE.C04
All
Features
What you need to know about building your biotech startup
All
Features
BaseLaunch Summer Get-Together 2023
All
Featured
Portfolio news
Versameb strengthens its Board of Directors
All
Featured
Portfolio news
Cimeio Therapeutics and Prime Medicine announce research collaboration
All
Features
How Swiss life sciences startups can compete globally
All
Features
Bridge Biotherapeutics’ partnering strategy and growth by external innovation
All
Featured
Portfolio news
Phialogics AG appoints Prof. Dr. Erich Schlick as Chairman of its Board of Directors
All
Featured
Portfolio news
Phialogics closed a €600k pre-seed financing round with HTGF
All
Featured
Portfolio news
Engimmune Therapeutics appoints Dr. Lars Nieba as Chief Executive Officer
All
Portfolio news
BaseLaunch Portfolio has raised over half a billion dollars to date!
All
Portfolio news
Alentis Therapeutics closes $105M funding round Led by Jeito Capital, Novo Holdings and RA Capital Management
All
Portfolio news
FimmCyte joins BaseLaunch Portfolio
All
Features
What startups need to know about term sheets, legal due diligence and employee incentives
All
Features
Building biotech companies and raising venture capital financing
All
Features
Raising $50M series A with Cimeio Therapeutics
All
Featured
Portfolio news
NXI Therapeutics Expands Management Team and Board Ahead of Next Growth Stage
Close Menu
About us
About us
Team
Work with us
Our offering
Our offering
FAQs
Portfolio
Success stories
Partners
Apply
Apply
FAQs
News
Events
Contact us
Sign up for our newsletter
Quarterly insights from our vibrant biotech ecosystem
SUBSCRIBE NOW